Botanical and Plant-Derived Drugs Worldwide Market by benturner06


									Botanical and Plant-Derived Drugs Worldwide Market
Because the use of plant-derived drugs has become so widespread, there is a great need to
develop an up-to-date base of market information about these products. More than four years
have passed since BCC Research published its first version of Botanical and Plant-Derived
Drugs: Global Markets. This report is an update of that one. Both analyze the key growth areas
in plant-derived drugs, develop quantitative market projections and discuss compliance with the
requirements for the botanical category of drugs, created in 2004, with its own U.S. FDA
regulations, guidelines and review process.


The present study meets this need by focusing on the global market for plant-derived drugs in
light of the most recent available information. In addition to looking at future and current
markets for a wide variety of new, reformulated and established products, the study will analyze
technological, environmental, legal/regulatory and socioeconomic developments that may
influence the market for plant-derived drugs.

This report provides an analysis of the emerging botanical drug industry and markets,
geographically and by therapeutic area. The future of plant-derived drugs as a whole is

More specific objectives are as follows:

      Identify and classify the botanical and plant-derived drugs that have been commercialized
       to date.
      Identify and evaluate the impact of factors that will drive future demand for botanical
       drugs with a focus too on plant-based drugs overall.
      Forecast the volume and value of shipments of botanical drugs through 2017.
      Describe botanical drugs that are currently in clinical testing or the approval stage and
       assess the probability that they will be commercialized successfully in the next five years.
      Forecast the potential market for these drug candidates, weighted to reflect the estimated
       probability that they will be commercialized.
      Identify the leading manufacturers of plant-derived drugs and the firms that may become
       important players in the next five years.
      Assess the long-term outlook for the plant-derived drug industry, taking into account
       market opportunities as well as technological, environmental, legal/regulatory and
       socioeconomic factors.

The report has been written for the entire pharmaceutical community, but is tailored especially
for readers with an interest in the marketing, management and public policy dimensions of
botanical drugs, including readers in the following:

      The pharmaceutical industry, especially companies supplying bulk or formulated plant-
       derived drugs or companies that are planning to enter this field.
      Medical research institutions.
      International organizations and governmental organizations with relevant responsibilities
       such as health, drug safety, conservation and the environment, and foreign trade.
      Investors.
      The financial and analyst community.

Buy a copy of this report @

Report details:
Published: January 2013
No. of Pages: 143
Price: Single User License: US$5450      Corporate User License: US$9350


This report is an analytical business tool whose primary purpose is to describe the botanical drug
industry with the overall plant-derived drug industry as a backdrop and the global market for
these drugs going forward.

For the purposes of this report, botanicals are those drugs that are FDA-approved under the
botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved
drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.

The study's main focus is on legal, prescription-required therapeutic medicines sold in the open
market. The study does not specifically cover herbals generally sold as dietary supplements (i.e.,
to promote overall "wellness" rather than to address a specific medical condition or symptoms).
While there is a substantial market for these products, the medical value of many of these
substances has not been demonstrated conclusively.

The study also does not cover the following:

      Underground or illicit drugs.
      Home remedies.
      Tribal medicines.
      Drugs derived from Archaea, bacteria and fungi (molds and yeasts).
      Non-medicinal plant substances such as laxative cellulose and pectin fiber.
      Intravenously delivered nutrients of plant origin, such as dextrose.
      Plant-derived substances serving as pharmaceutical excipients, such as starch,
       methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.
      Plant substances serving in cosmetics, toiletries and personal care products.
      Microbial fermentation products, even those made with culture media incorporating corn
       steep liquor, starch or other plant-derived nutrients.
      Marine life.

The format of the study is organized around the following topics:

      Major types and applications of botanical drugs with plant-derived drugs as their
      Industry structure.
      Market size and segmentation, including the breakdown of sales by therapeutic area and
       geographic area.
      Market drivers.
      Market projections through 2017.
      Competition.
      Observations and conclusions regarding the future of the botanical and plant-derived drug


Both primary and secondary research methods were used in preparing this research report. The
findings and conclusions contained in this report are based on information gathered from
development companies and sales and manufacturers involved with primarily, botanical drugs as
defined by the U.S. FDA and secondarily, the larger world of plant-derived drugs, which
encompasses botanical drugs as a subsegment. Additional data were obtained from extensive
reviews of secondary sources such as trade publications, trade associations, company literature
and online databases.


In the case of commercial drugs, the study starts by projecting the demand for various types of
medical applications, such as chemotherapy drugs, asthma and medicine, which use plant-
derived drugs as part of the therapy. The implied demand for plant-derived drugs is then
estimated based on historical relationships, adjusted to reflect such factors as the availability of
alternative, non-plant-derived drugs; price relationships; and other buyer criteria as well as other
information from relevant companies.


The approach described above is useful mainly for drugs that are already in commercial use. A
somewhat different approach is used to project demand for drugs that are still in the development
or regulatory testing and approval processes, but are expected to be commercialized in the 2012
to 2017 time frame.
In some cases, a new plant-derived drug's developers or other industry analysts are projecting
that the drug will be commercialized by a particular year (e.g., 2017). Where this is not the case,
BCC uses the timeline for the U.S. FDA approval process as a yardstick for evaluating the
likelihood that a particular plant-based drug will be commercialized in the next five years. (Even
in cases where developers are projecting a particular year, BCC has used the FDA approval
process timeline as a kind of reality check.)

In the United States, it takes 12 years, on average, for an experimental drug to complete clinical
testing and receive FDA approval, as shown below.

Since the market projections in this report include only products that are likely to be
commercialized in the five-year period of 2012 to 2017, the projections are limited to plant-
derived drug candidates that are likely to receive FDA approval by 2017. This in turn generally
limits the field of drugs that are in Phase III clinical trials or in the final FDA approval process.

Get a copy of your report @

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
+ 1 888 391 5441

Connect With Us:

To top